Cervista™ HPV HR 95-438 PRD-00804

Total Page:16

File Type:pdf, Size:1020Kb

Cervista™ HPV HR 95-438 PRD-00804 Cervista™ Cervista™ HPV HR 95-438 PRD-00804 An in vitro diagnostic test for the detection of DNA from14 high-risk Human Papillomavirus (HPV) types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in Cervical Specimens. -15°C 95-438: -30°C PRD-00804: Do NOT store in frost-free freezer. Protect from light. Table of Contents General Information .......................................................................................................................... 2 Abbreviations Used ........................................................................................................................... 3 Summary and Explanation of the Test ............................................................................................. 3 Principles of the Procedure .............................................................................................................. 4 Reagents Provided ............................................................................................................................ 5 Warnings and Precautions ............................................................................................................... 6 Reagent Storage and Handling Requirements ................................................................................ 6 Additional Reagents and Materials .................................................................................................. 6 Materials Required, But Not Provided, for Manual Testing ............................................................ 6 Materials Required, But Not Provided, for Automated Testing ...................................................... 7 Specimen Collection and Storage for Analysis ............................................................................... 7 Automated Test Procedure for the Cervista HTA System ............................................................... 7 Manual Test Procedure for Cervista HPV HR .................................................................................. 7 Procedural Notes and Precautions .................................................................................................. 9 Interpretation of Results ................................................................................................................... 9 Quality Control ................................................................................................................................ 11 Limitations ....................................................................................................................................... 12 Expected Results............................................................................................................................. 13 Performance Characteristics .......................................................................................................... 14 Test Performance Characteristics Using the Cervista HTA System ............................................ 27 Troubleshooting .............................................................................................................................. 31 Bibliography .................................................................................................................................... 36 Contact Information: ....................................................................................................................... 37 Invader™ Cervista™ General Information Intended Use The Cervista HPV HR test is an in vitro diagnostic test for the qualitative detection of DNA from 14 high-risk Human Papillomavirus (HPV) types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) in cervical specimens. The Cervista HPV HR test cannot determine the specific HPV type present. The Cervista HPV HR test uses the Invader™ chemistry, a signal amplification method for detection of specific nucleic acid sequences. This method uses two types of isothermal reactions: a primary reaction that occurs on the targeted DNA sequence and a secondary reaction that produces a fluorescent signal. The Cervista HPV HR test is indicated: 1) To screen patients with atypical squamous cells of undetermined significance (ASC-US) cervical cytology results to determine the need for referral to colposcopy. 2) In women 30 years and older the Cervista HPV HR test can be used with cervical cytology to adjunctively screen to assess the presence or absence of high-risk HPV types. This information, together with the physician’s assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management. Cervical specimens that may be tested with the Cervista HPV HR test include the following preservation system collection media and collection devices: • ThinPrep™ Pap Test PreservCyt™ Solution • Broom-type device (e.g., Rovers Cervex® Brush, Wallach Papette®), or Endocervical Brush/Spatula The Cervista HPV HR test may be performed either manually or using the automated Cervista High Throughput Automation (HTA) system. Warnings • The Cervista HPV HR test is not intended for use as a screening device for women under age 30 with normal cervical cytology. • The Cervista HPV HR test is not intended to substitute for regular cervical cytology screening. • Detection of HPV using the Cervista HPV HR test does not differentiate HPV types and cannot evaluate persistence of any one type. • The use of this test has not been evaluated for the management of women with prior cytological or histological abnormalities, hysterectomy, who are pregnant, postmenopausal, or who have other risk factors (e.g., HIV+, immunocompromised, history of STI). • The Cervista HTA system is only to be used for Cervista HPV HR testing and cannot be utilized for testing with the Cervista HPV 16/18 test. • The Cervista HPV HR test is designed to enhance existing methods for the detection of cervical disease and should be used in conjunction with clinical information derived from other diagnostic and screening tests, physical examinations, and full medical history in accordance with appropriate patient management procedures. • Cervista HPV HR test results should not be used as the sole basis for clinical assessment and treatment of patients. Cervista HPV HR 2 15-3100, Rev. 105 Invader™ Cervista™ Abbreviations Used ASC-US: Atypical squamous cells of undetermined significance CIN: Cervical intraepithelial neoplasia CLSI Clinical and Laboratory Standards Institute DNA: Deoxyribonucleic acid FAM: Carboxyfluorescein dye Red: Redmond® red dye FRET: Fluorescence resonance energy transfer FOZ: Fold over zero (sample or control signal divided by No Target Control signal) gDNA: Genomic DNA HIST2H2BE: Human histone 2 gene, H2be gene HPV: Human papillomavirus HR: High-risk HTA High Throughput Automation LoB Limit of Blank LoD Limit of Detection Max. Maximum Min. Minimum NILM: Negative for intraepithelial lesion or malignancy. This category encompasses the previous categories of "within normal limits" and "benign cellular changes”. NTC: No target control Oligo: Oligonucleotide Pap: Papanicolaou cervical cytology test RFU: Relative fluorescence unit Summary and Explanation of the Test Over 100 HPV types have been documented in the literature, approximately 40 of which infect the anogenital area and are transmitted sexually. Anogenital HPV is associated with virtually all cancers of the cervix.1 Cervical cancer has previously been shown to be highly preventable when cytological and HPV screening programs are employed to facilitate the detection and treatment of pre-cancerous lesions. Of the sexually transmitted types of HPV, 14 oncogenic genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), are considered high-risk (HR) HPV types due to their strong association with cervical cancers (relative to low risk HPV types, which have little or no association with cervical cancer).2,3 Still, the vast majority of high-risk HPV infections are cleared.4 Very few high-risk HPV DNA positive women develop cytologic high-grade SIL (HSIL) indicating underlying CIN2-3 or cancer.5 The absolute risk of developing an incident cytologic abnormality following a HR HPV infection is known to vary in different populations. The presence of high-risk HPV DNA in conjunction with an equivocal or ambiguous cytology result (ASC-US) places a woman at increased risk for having an underlying cervical intraepithelial neoplasia 2 or 3 (CIN2 or CIN3).6,7,8 CIN3, while occurring in only approximately 5% of ASC-US cases,9 is an immediate precursor to cervical cancer and consequently its detection is very important for patient management.3 Therefore, the identification of those women with ASC-US cytology in conjunction with a high-risk HPV infection is a useful aid for clinicians to decide who should be monitored more aggressively.3,6,10,11 Current scientific literature suggests that persistent infection with high-risk HPV is the main risk factor for development of high-grade cervical neoplasia and cancer.4,12,13,14 Apparent persistence may represent continuous infection with a single HPV type, with multiple HPV types, or reinfection. Nonetheless, women with normal cervical cytology who are HR HPV negative appear to be at low risk for having or developing cervical precancerous lesions.15,16 Beginning in 2002, patient management guidelines have been published by various groups of U.S. healthcare professionals that recommend how women should be screened for cervical cancer according to age, the presence of cytological
Recommended publications
  • Expression Analysis of Progesterone‑Regulated Mirnas in Cells Derived from Human Glioblastoma
    MOLECULAR MEDICINE REPORTS 23: 475, 2021 Expression analysis of progesterone‑regulated miRNAs in cells derived from human glioblastoma DIANA ELISA VELÁZQUEZ‑VÁZQUEZ1, AYLIN DEL MORAL‑MORALES1, JENIE MARIAN CRUZ‑BURGOS2, EDUARDO MARTÍNEZ‑MARTÍNEZ3, MAURICIO RODRÍGUEZ‑DORANTES2 and IGNACIO CAMACHO‑ARROYO1 1Unidad de Investigación en Reproducción Humana, Instituto Nacional de Perinatología‑Facultad de Química, Universidad Nacional Autónoma de México, Mexico City 04510; 2Oncogenomics Laboratory, The National Institute of Genomic Medicine; 3Laboratory of Cell Communication and Extracellular Vesicles, The National Institute of Genomic Medicine, Mexico City 14610, Mexico Received August 16, 2020; Accepted February 2, 2021 DOI: 10.3892/mmr.2021.12114 Abstract. Glioblastomas (GBMs) are the most frequent and is characterized by being highly infiltrative, angiogenic and malignant type of brain tumor. It has been reported that resistant to chemotherapy and radiotherapy. The medical progesterone (P4) regulates the progression of GBMs by modi‑ history of patients with GBM is short as few of them survive fying the expression of genes that promote cell proliferation, more than one year (1‑3). GBM is mainly diagnosed in adults migration and invasion; however, it is not fully understood >50 years old, but it can occur at any age and the incidence is how these processes are regulated. It is possible that P4 medi‑ higher in men than in women (3:2) (4). ates some of these effects through changes in the microRNA Studies have focused on the identification of new biomarkers (miRNA) expression profile in GBM cells. The present study and therapeutic agents in GBM. Of particular interest are the investigated the effects of P4 on miRNAs expression profile microRNAs (miRNAs), which are single‑stranded, short, in U‑251MG cells derived from a human GBM.
    [Show full text]
  • A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
    Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context.
    [Show full text]
  • Genomic and Functional Profiling of Duplicated Chromosome
    Human Molecular Genetics, 2006, Vol. 15, No. 6 853–869 doi:10.1093/hmg/ddl004 Advance Access published on January 30, 2006 Genomic and functional profiling of duplicated chromosome 15 cell lines reveal regulatory alterations in UBE3A-associated ubiquitin–proteasome pathway processes Colin A. Baron1, Clifford G. Tepper2, Stephenie Y. Liu1, Ryan R. Davis1, Nicholas J. Wang3, N. Carolyn Schanen4 and Jeffrey P. Gregg1,* 1Department of Pathology and 2Department of Biochemistry and Molecular Medicine, University of California, Davis School of Medicine, Sacramento, CA 95817, USA, 3Department of Human Genetics, University of 4 California–Los Angeles, Los Angeles, CA, USA and Center for Pediatric Research, Nemours Biomedical Research, Downloaded from Alfred I. duPont Hospital for Children, Wilmington, DE, USA Received November 21, 2005; Revised and Accepted January 25, 2006 Autism is a complex neurodevelopmental disorder having both genetic and epigenetic etiological elements. hmg.oxfordjournals.org Isodicentric chromosome 15 (Idic15), characterized by duplications of the multi-disorder critical region of 15q11–q14, is a relatively common cytogenetic event. When the duplication involves maternally derived con- tent, this abnormality is strongly correlated with autism disorder. However, the mechanistic links between Idic15 and autism are ill-defined. To gain insight into the potential role of these duplications, we performed a comprehensive, genomics-based characterization of an in vitro model system consisting of lymphoblast cell lines derived from individuals with both autism and Idic15. Array-based comparative genomic hybridiz- ation using commercial single nucleotide polymorphism arrays was conducted and found to be capable of by guest on December 17, 2010 sub-classifying Idic15 samples by virtue of the lengths of the duplicated chromosomal region.
    [Show full text]
  • A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
    Author Manuscript Published OnlineFirst on July 23, 2019; DOI: 10.1158/2159-8290.CD-19-0393 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A Mutation in Histone H2B Represents A New Class Of Oncogenic Driver Richard L. Bennett1, Aditya Bele1, Eliza C. Small2, Christine M. Will2, Behnam Nabet3, Jon A. Oyer2, Xiaoxiao Huang1,9, Rajarshi P. Ghosh4, Adrian T. Grzybowski5, Tao Yu6, Qiao Zhang7, Alberto Riva8, Tanmay P. Lele7, George C. Schatz9, Neil L. Kelleher9 Alexander J. Ruthenburg5, Jan Liphardt4 and Jonathan D. Licht1 * 1 Division of Hematology/Oncology, University of Florida Health Cancer Center, Gainesville, FL 2 Division of Hematology/Oncology, Northwestern University 3 Department of Cancer Biology, Dana Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School 4 Department of Bioengineering, Stanford University 5 Department of Molecular Genetics and Cell Biology, The University of Chicago 6 Department of Chemistry, Tennessee Technological University 7 Department of Chemical Engineering, University of Florida 8 Bioinformatics Core, Interdisciplinary Center for Biotechnology Research, University of Florida 9 Department of Chemistry, Northwestern University, Evanston IL 60208 Running title: Histone mutations in cancer *Corresponding Author: Jonathan D. Licht, MD The University of Florida Health Cancer Center Cancer and Genetics Research Complex, Suite 145 2033 Mowry Road Gainesville, FL 32610 352-273-8143 [email protected] Disclosures: The authors have no conflicts of interest to declare Downloaded from cancerdiscovery.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 23, 2019; DOI: 10.1158/2159-8290.CD-19-0393 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Investigation of Differentially Expressed Genes in Nasopharyngeal Carcinoma by Integrated Bioinformatics Analysis
    916 ONCOLOGY LETTERS 18: 916-926, 2019 Investigation of differentially expressed genes in nasopharyngeal carcinoma by integrated bioinformatics analysis ZhENNING ZOU1*, SIYUAN GAN1*, ShUGUANG LIU2, RUjIA LI1 and jIAN hUANG1 1Department of Pathology, Guangdong Medical University, Zhanjiang, Guangdong 524023; 2Department of Pathology, The Eighth Affiliated hospital of Sun Yat‑sen University, Shenzhen, Guangdong 518033, P.R. China Received October 9, 2018; Accepted April 10, 2019 DOI: 10.3892/ol.2019.10382 Abstract. Nasopharyngeal carcinoma (NPC) is a common topoisomerase 2α and TPX2 microtubule nucleation factor), malignancy of the head and neck. The aim of the present study 8 modules, and 14 TFs were identified. Modules analysis was to conduct an integrated bioinformatics analysis of differ- revealed that cyclin-dependent kinase 1 and exportin 1 were entially expressed genes (DEGs) and to explore the molecular involved in the pathway of Epstein‑Barr virus infection. In mechanisms of NPC. Two profiling datasets, GSE12452 and summary, the hub genes, key modules and TFs identified in GSE34573, were downloaded from the Gene Expression this study may promote our understanding of the pathogenesis Omnibus database and included 44 NPC specimens and of NPC and require further in-depth investigation. 13 normal nasopharyngeal tissues. R software was used to identify the DEGs between NPC and normal nasopharyngeal Introduction tissues. Distributions of DEGs in chromosomes were explored based on the annotation file and the CYTOBAND database Nasopharyngeal carcinoma (NPC) is a common malignancy of DAVID. Gene ontology (GO) and Kyoto Encyclopedia of occurring in the head and neck. It is prevalent in the eastern Genes and Genomes (KEGG) pathway enrichment analysis and southeastern parts of Asia, especially in southern China, were applied.
    [Show full text]
  • WNT16 Is a New Marker of Senescence
    Table S1. A. Complete list of 177 genes overexpressed in replicative senescence Value Gene Description UniGene RefSeq 2.440 WNT16 wingless-type MMTV integration site family, member 16 (WNT16), transcript variant 2, mRNA. Hs.272375 NM_016087 2.355 MMP10 matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA. Hs.2258 NM_002425 2.344 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), mRNA. Hs.375129 NM_002422 2.300 HIST1H2AC Histone cluster 1, H2ac Hs.484950 2.134 CLDN1 claudin 1 (CLDN1), mRNA. Hs.439060 NM_021101 2.119 TSPAN13 tetraspanin 13 (TSPAN13), mRNA. Hs.364544 NM_014399 2.112 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 2.070 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 2.026 DCBLD2 discoidin, CUB and LCCL domain containing 2 (DCBLD2), mRNA. Hs.203691 NM_080927 2.007 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), mRNA. Hs.594481 NM_002575 2.004 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 1.989 OBFC2A Oligonucleotide/oligosaccharide-binding fold containing 2A Hs.591610 1.962 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 1.947 PLCB4 phospholipase C, beta 4 (PLCB4), transcript variant 2, mRNA. Hs.472101 NM_182797 1.934 PLCB4 phospholipase C, beta 4 (PLCB4), transcript variant 1, mRNA. Hs.472101 NM_000933 1.933 KRTAP1-5 keratin associated protein 1-5 (KRTAP1-5), mRNA. Hs.534499 NM_031957 1.894 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 1.884 CYTL1 cytokine-like 1 (CYTL1), mRNA. Hs.13872 NM_018659 tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain (TNFRSF10D), 1.848 TNFRSF10D Hs.213467 NM_003840 mRNA.
    [Show full text]
  • A Bacterial Protein Targets the BAHD1 Chromatin Complex to Stimulate Type III Interferon Response
    A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response Alice Lebreton, Goran Lakisic, Viviana Job, Lauriane Fritsch, To Nam Tham, Ana Camejo, Pierre-Jean Matteï, Béatrice Regnault, Marie-Anne Nahori, Didier Cabanes, et al. To cite this version: Alice Lebreton, Goran Lakisic, Viviana Job, Lauriane Fritsch, To Nam Tham, et al.. A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response. Science, American Association for the Advancement of Science, 2011, 331 (6022), pp.1319-21. 10.1126/sci- ence.1200120. cea-00819299 HAL Id: cea-00819299 https://hal-cea.archives-ouvertes.fr/cea-00819299 Submitted on 26 Jul 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Lebreton et al. Science 2011 doi:10.1126/science.1200120 A Bacterial Protein Targets the BAHD1 Chromatin Complex to Stimulate Type III Interferon Response Alice Lebreton1,2,3, Goran Lakisic4, Viviana Job5, Lauriane Fritsch6, To Nam Tham1,2,3, Ana Camejo7, Pierre-Jean Matteï5, Béatrice Regnault8, Marie-Anne Nahori1,2,3, Didier Cabanes7, Alexis Gautreau4, Slimane Ait-Si-Ali6, Andréa Dessen5, Pascale Cossart1,2,3* and Hélène Bierne1,2,3* 1.
    [Show full text]
  • Exosomes Involved in Cholesterol Metabolism Process of Patients with Spinal Cord Injury in the Acute Phase
    ORIGINAL RESEARCH published: 09 July 2021 doi: 10.3389/fninf.2021.662967 Bioinformatic Analysis of the Proteome in Exosomes Derived From Plasma: Exosomes Involved in Cholesterol Metabolism Process of Patients With Spinal Cord Injury in the Acute Phase Chunshuai Wu 1†, Jinjuan Yu 2†, Guanhua Xu 1, Hong Gao 1, Yue Sun 1, Jiayi Huang 1, Li Sun 1, Xu Zhang 1 and Zhiming Cui 1* 1 Department of Spine Surgery, Nantong First People’s Hospital, The Affiliated Hospital 2 of Nantong University, Nantong, China, 2 Department of Administrative Office, The Third People’s Hospital of Nantong, Nantong, China Edited by: Sandeep Kumar Dhanda, St. Jude Children’s Research Hospital, Spinal cord injury (SCI) is a common but severe disease caused by traffic accidents. United States Coronary atherosclerotic heart disease (CHD) caused by dyslipidemia is known as the Reviewed by: leading cause of death in patients with SCI. However, the quantitative analysis showed Prashanth N. Suravajhala, Birla Institute of Scientific that the cholesterol and lipoprotein concentrations in peripheral blood (PB) did not Research, India change significantly within 48 h after SCI. Due to the presence of the Blood spinal Chandrabose Selvaraj, Alagappa University, India cord barrier (BSCB), there are only few studies concerning the plasma cholesterol Aditya Ambati, metabolism in the acute phase of SCI. Exosomes have a smaller particle size, which Stanford University, United States enables them relatively less limitation of BSCB. This study uses exosomes derived from *Correspondence: the plasma of 43 patients in the acute phase of SCI and 71 patients in the control Zhiming Cui [email protected] group as samples.
    [Show full text]
  • Targeting the DEK Oncogene in Head and Neck Squamous Cell Carcinoma: Functional and Transcriptional Consequences
    Targeting the DEK oncogene in head and neck squamous cell carcinoma: functional and transcriptional consequences A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements to the degree of Doctor of Philosophy (Ph.D.) in the Department of Cancer and Cell Biology of the College of Medicine March 2015 by Allie Kate Adams B.S. The Ohio State University, 2009 Dissertation Committee: Susanne I. Wells, Ph.D. (Chair) Keith A. Casper, M.D. Peter J. Stambrook, Ph.D. Ronald R. Waclaw, Ph.D. Susan E. Waltz, Ph.D. Kathryn A. Wikenheiser-Brokamp, M.D., Ph.D. Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide with over 50,000 new cases in the United States each year. For many years tobacco and alcohol use were the main etiological factors; however, it is now widely accepted that human papillomavirus (HPV) infection accounts for at least one-quarter of all HNSCCs. HPV+ and HPV- HNSCCs are studied as separate diseases as their prognosis, treatment, and molecular signatures are distinct. Five-year survival rates of HNSCC hover around 40-50%, and novel therapeutic targets and biomarkers are necessary to improve patient outcomes. Here, we investigate the DEK oncogene and its function in regulating HNSCC development and signaling. DEK is overexpressed in many cancer types, with roles in molecular processes such as transcription, DNA repair, and replication, as well as phenotypes such as apoptosis, senescence, and proliferation. DEK had never been previously studied in this tumor type; therefore, our studies began with clinical specimens to examine DEK expression patterns in primary HNSCC tissue.
    [Show full text]
  • Human Papillomavirus Oncoprotein E7 Dysregulates Immune
    HUMAN PAPILLOMAVIRUS ONCOPROTEIN E7 DYSREGULATES IMMUNE RESPONSES THROUGH EPIGENETIC MANIPULATION by LOUIS J CICCHINI B.S., University of Arizona, 2009 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Molecular Biology 2016 This thesis for the Doctor of Philosophy degree by Louis J Cicchini has been approved for the Molecular Biology Program by Rytis Prekeris, Chair Dohun Pyeon, Advisor James Hagman Thomas E. Morrison Xiao-Jing Wang Date: August 18, 2016 ii Cicchini, Louis J. (PhD, Molecular Biology) Human Papillomavirus Oncoprotein E7 Dysregulates Immune Responses through Epigenetic Manipulation Thesis directed by Associate Professor Dohun Pyeon ABSTRACT High-risk human papillomaviruses (HPVs) are causally associated with multiple human cancers. Previous studies have shown that the HPV oncoprotein E7 induces immune suppression; however, the underlying mechanisms remain unknown. We report that, while expression of many proinflammatory chemokines increases throughout HPV-positive cancer progression, CXCL14 is dramatically downregulated by promoter hypermethylation in an E7- dependent manner. Our in vivo mouse models revealed that restoration of Cxcl14 expression in HPV-positive mouse oropharyngeal carcinoma cells clears tumors in immunocompetent syngeneic mice, but not in Rag1-deficient mice. Further, restoration of Cxcl14 expression significantly increases natural killer (NK), CD4+ T, and CD8+ T cell infiltration into the tumor-draining lymph nodes in vivo. In vitro transwell migration assays show that restoration of Cxcl14 expression induces chemotaxis of NK, CD4+ T, and CD8+ T cells. These findings suggest that high-risk HPV E7 is likely to dysregulate host gene expression in order to persist by modulating host DNA methylation.
    [Show full text]
  • High Resolution Annotation of Zebrafish Transcriptome Using Long-Read Sequencing
    Downloaded from genome.cshlp.org on October 7, 2021 - Published by Cold Spring Harbor Laboratory Press Resource High resolution annotation of zebrafish transcriptome using long-read sequencing German Nudelman,1,2,8 Antonio Frasca,3,8 Brandon Kent,4 Kirsten C. Sadler,5 Stuart C. Sealfon,1,2,3 Martin J. Walsh,3,6,7 and Elena Zaslavsky1,2 1Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 2Center for Advanced Research on Diagnostic Assays (CARDA), Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 4Department of Development and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 5Program in Biology, New York University Abu Dhabi, Abu Dhabi, UAE; 6Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA; 7The Mount Sinai Center for RNA Biology and Medicine, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA With the emergence of zebrafish as an important model organism, a concerted effort has been made to study its transcrip- tome. This effort is limited, however, by gaps in zebrafish annotation, which are especially pronounced concerning transcripts dynamically expressed during zygotic genome activation (ZGA). To date, short-read sequencing has been the principal technology for zebrafish transcriptome annotation. In part because these sequence reads are too short for assem- bly methods to resolve the full complexity of the transcriptome, the current annotation is rudimentary.
    [Show full text]
  • Homeobox Gene IRX1 Is a Tumor Suppressor Gene in Gastric Carcinoma
    Oncogene (2010) 29, 3908–3920 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc ORIGINAL ARTICLE Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma X Guo1,3, W Liu1,3, Y Pan1,PNi2,JJi1, L Guo1, J Zhang1,JWu1, J Jiang1, X Chen1, Q Cai1, JLi1, J Zhang1,QGu1, B Liu1, Z Zhu1 and Y Yu1 1Department of Surgery of Shanghai Ruijin Hospital and Shanghai Institute of Digestive Surgery, Shanghai, PR China and 2Department of Clinical Biochemistry, Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, PR China The IRX1 tumor suppressor gene is located on 5p15.33, a locatedonLOHloci.Ourgrouppreviouslycharacterized cancer susceptibility locus. Loss of heterozygosity of a high frequency of LOH at 5p15.33 in human gastric 5p15.33 in gastric cancer was identified in our previous cancer. We hypothesized that genes located on this locus work. In this study, we analyzed the molecular features may contribute to the pathogenesis of gastric cancer (Lu and function of IRX1. We found that IRX1 expression et al., 2005). IRX1 is harbored in this chromosome locus was lost or reduced in gastric cancer. However, no and belongs to the Iroquois homeobox gene family, which mutations were identified in IRX1-encoding regions. IRX1 has six members from IRX1 to IRX6. IRX1 is closely transcription was suppressed by hypermethylation, and the related to embryonic development, including foregut expression of IRX1 mRNA was partially restored in organs such as the lung (Ferguson et al.,1998;Becker gastric cancer cells after 5-Aza-dC treatment. Restoring et al., 2001; van Tuyl et al., 2006; Alarcon et al., 2008).
    [Show full text]